Modified CEUS LI-RADS With Perfluorobutane in Patients at High-Risk for Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.

IF 2.4 3区医学 Q2 ACOUSTICS

Ultrasound in Medicine and Biology Pub Date : 2025-07-10 DOI:10.1016/j.ultrasmedbio.2025.05.024

Jifan Chen, Jianing Zhu, Jiaxing Shen, Yuhan Fu, Fei Gao, Jing Wang, Peile Jin, Tao Lin, Yang Sun, Qiu Chen, Ying Zhang, Guowei Wang, Chao Zhang, Jianhua Zhou, Xiang Jing, Pintong Huang

{"title":"Modified CEUS LI-RADS With Perfluorobutane in Patients at High-Risk for Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.","authors":"Jifan Chen, Jianing Zhu, Jiaxing Shen, Yuhan Fu, Fei Gao, Jing Wang, Peile Jin, Tao Lin, Yang Sun, Qiu Chen, Ying Zhang, Guowei Wang, Chao Zhang, Jianhua Zhou, Xiang Jing, Pintong Huang","doi":"10.1016/j.ultrasmedbio.2025.05.024","DOIUrl":null,"url":null,"abstract":"<p><p>Contrast-enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) 2017 version is based on pure-blood pool contrast agent, potentially unsuitable for perfluorobutane contrast agent with the Kupffer phase. This article aimed to compare the diagnostic performance of unmodified CEUS LI-RADS and modified CEUS LI-RADS using perfluorobutane for hepatocellular carcinoma by integrating published and original data from three medical centers. Comparison between unmodified and modified CEUS LI-RADS with perfluorobutane involved ranking the diagnostic odds ratio (DOR) and superiority index (SI) using an ANOVA arm-based model. This meta-analysis included nine studies and our original data, encompassing 1505 patients with 1622 lesions. The summarized sensitivity of the modified CEUS LI-RADS was higher than that of the unmodified version (0.77 [0.72-0.81] vs. 0.70 [0.63-0.76]), while specificity was similar for both (0.86 [0.78-0.91] vs. 0.86 [0.77-0.92]). The general diagnostic performance of the modified CEUS LI-RADS was superior to the unmodified version, indicated by a higher DOR (16.98 [11.65-23.43] vs. 12.51 [8.11-18.44], p = 0.02) and SI (1.59 [1.00-3.00] vs. 0.80 [0.33-1.00], p = 0.02). Modified CEUS LI-RADS may be of better diagnostic performance, offering higher sensitivity without compromising specificity.</p>","PeriodicalId":49399,"journal":{"name":"Ultrasound in Medicine and Biology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ultrasound in Medicine and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ultrasmedbio.2025.05.024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ACOUSTICS","Score":null,"Total":0}

引用次数: 0

Abstract

Contrast-enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) 2017 version is based on pure-blood pool contrast agent, potentially unsuitable for perfluorobutane contrast agent with the Kupffer phase. This article aimed to compare the diagnostic performance of unmodified CEUS LI-RADS and modified CEUS LI-RADS using perfluorobutane for hepatocellular carcinoma by integrating published and original data from three medical centers. Comparison between unmodified and modified CEUS LI-RADS with perfluorobutane involved ranking the diagnostic odds ratio (DOR) and superiority index (SI) using an ANOVA arm-based model. This meta-analysis included nine studies and our original data, encompassing 1505 patients with 1622 lesions. The summarized sensitivity of the modified CEUS LI-RADS was higher than that of the unmodified version (0.77 [0.72-0.81] vs. 0.70 [0.63-0.76]), while specificity was similar for both (0.86 [0.78-0.91] vs. 0.86 [0.77-0.92]). The general diagnostic performance of the modified CEUS LI-RADS was superior to the unmodified version, indicated by a higher DOR (16.98 [11.65-23.43] vs. 12.51 [8.11-18.44], p = 0.02) and SI (1.59 [1.00-3.00] vs. 0.80 [0.33-1.00], p = 0.02). Modified CEUS LI-RADS may be of better diagnostic performance, offering higher sensitivity without compromising specificity.

查看原文本刊更多论文

全氟丁烷改良超声造影LI-RADS在高危肝细胞癌患者中的应用：系统综述和网络荟萃分析

对比增强超声肝脏成像报告和数据系统（CEUS LI-RADS） 2017版本基于纯血池造影剂，可能不适合Kupffer期的全氟丁烷造影剂。本文旨在通过整合来自三个医疗中心的已发表和原始数据，比较未修饰的超声造影LI-RADS和使用全氟丁烷修饰的超声造影LI-RADS对肝细胞癌的诊断性能。使用基于方差分析臂的模型对未修改的和修改的全氟丁烷CEUS LI-RADS进行比较，包括对诊断优势比（DOR）和优势指数（SI）进行排序。这项荟萃分析包括9项研究和我们的原始数据，包括1505名患者和1622个病变。改良版CEUS LI-RADS的总敏感性高于未改良版（0.77 [0.72-0.81]vs. 0.70[0.63-0.76]），而两者的特异性相似（0.86 [0.78-0.91]vs. 0.86[0.77-0.92]）。改良版CEUS LI-RADS的一般诊断性能优于未改良版，DOR（16.98[11.65-23.43]比12.51 [8.11-18.44],p = 0.02）和SI（1.59[1.00-3.00]比0.80 [0.33-1.00],p = 0.02）更高。改良的超声造影LI-RADS可能具有更好的诊断性能，在不影响特异性的情况下提供更高的灵敏度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ultrasound in Medicine and Biology 医学-核医学

CiteScore

6.20

自引率

6.90%

发文量

325

审稿时长

70 days

期刊介绍： Ultrasound in Medicine and Biology is the official journal of the World Federation for Ultrasound in Medicine and Biology. The journal publishes original contributions that demonstrate a novel application of an existing ultrasound technology in clinical diagnostic, interventional and therapeutic applications, new and improved clinical techniques, the physics, engineering and technology of ultrasound in medicine and biology, and the interactions between ultrasound and biological systems, including bioeffects. Papers that simply utilize standard diagnostic ultrasound as a measuring tool will be considered out of scope. Extended critical reviews of subjects of contemporary interest in the field are also published, in addition to occasional editorial articles, clinical and technical notes, book reviews, letters to the editor and a calendar of forthcoming meetings. It is the aim of the journal fully to meet the information and publication requirements of the clinicians, scientists, engineers and other professionals who constitute the biomedical ultrasonic community.